NasdaqCM - Nasdaq Real Time Price USD

Anebulo Pharmaceuticals, Inc. (ANEB)

0.9950

+0.0250

+(2.58%)

As of 10:08:24 AM EDT. Market Open.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas, February 14, 2025--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2024, and recent updates.

Business Wire 2 months ago

ANEB
+2.58%
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

As the U.S. stock market reacts to tariff news and a wave of earnings reports, major indices like the S&P 500 and Nasdaq Composite are seeing upward movement. For investors considering smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area with potential value. These stocks can offer unique growth opportunities, especially when backed by strong financials, as we explore several promising candidates in this article.

Simply Wall St. 2 months ago

ANEB
+2.58%
GDTC
3 US Penny Stocks With Market Caps Under $800M

As U.S. equities face a challenging period, with the Dow and S&P 500 on track for their worst month since April, investors are increasingly exploring alternative investment avenues. Penny stocks, despite their somewhat outdated name, continue to attract attention as they represent smaller or less-established companies that might offer value amidst market volatility. By focusing on those with strong financials and potential for growth, investors can uncover opportunities in this niche segment...

Simply Wall St. 3 months ago

ANEB
+2.58%
RSKD

SPWH
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant

Anebulo Pharmaceuticals (ANEB) announced a regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children. Anebulo met with FDA to

TipRanks 3 months ago

ANEB
+2.58%
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

AUSTIN, Texas, December 23, 2024--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Business Wire 3 months ago

ANEB
+2.58%
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas, November 13, 2024--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Business Wire 5 months ago

ANEB
+2.58%
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas, September 25, 2024--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Business Wire 6 months ago

ANEB
+2.58%
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 6 months ago

ANEB
+2.58%
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

AUSTIN, Texas, July 22, 2024--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to support the development of intravenous selonabant, f

Business Wire 8 months ago

ANEB
+2.58%
Lifecore Biomedical Announces Cooperation Agreement with 22NW

Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the BoardCHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreement (the “Agreement”) with 22NW, LP (“22NW”), which provides for the addition of Humberto Antunes, Jason Aryeh,

GlobeNewswire 9 months ago

ANEB
+2.58%
LGND

LGNDZ
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas, May 15, 2024--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2024, and recent updates.

Business Wire 11 months ago

ANEB
+2.58%

Performance Overview

Return	ANEB	S&P 500 (^GSPC)
YTD	-40.77%	-7.34%
1-Year	-64.34%	+7.45%
3-Year	-76.86%	+27.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

3 US Penny Stocks With Market Caps Under $800M

Anebulo Pharmaceuticals collaborates with FDA to advance selonabant

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Lifecore Biomedical Announces Cooperation Agreement with 22NW

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Performance Overview